Journal of Clinical Oncology
Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0
PURPOSE To provide recommendations on use of medical therapies for patients with stage I-III hormone receptor-positive, HER2-negative breast cancer. METHODS An Expert Panel including patient representation completed a systematic review of the evidence and formulated recommendations for practice. Eligible studies included patients with stage I-III hormone receptor-positive, HER2-negative breast cancer and evaluated neoadjuvant or adjuvant chemotherapy, endocrine therapy, immunotherapy, or targeted therapy. Outcomes …